Learn about the MEVPRO clinical trial program researching a new potential treatment for men with metastatic prostate cancer
About 1 in 8 men will be diagnosed with prostate cancer in their lifetime.
It is estimated that almost 300,000 men will be diagnosed in the US each year.
The MEVPRO program is conducting a series of clinical trials to find out if a study medicine called mevrometostat is safe and works to slow down or stop the growth of metastatic prostate cancer.
As you consider your next steps, thank you for taking time to learn more about the MEVPRO prostate cancer clinical trials.
Watch a short video about the study medicine
About mevrometostat
The study medicine is called mevrometostat and is taken as tablets by mouth twice-a-day.
Prostate cancer cells need hormones (such as testosterone) to grow and divide and can often become resistant to hormone therapy and continue to progress and spread to other parts of the body.
EZH2 is a gene that directs the production of proteins which control the growing, dividing or repairing of cells. In some people, the EZH2 gene may become abnormal or make too much of the proteins, which can cause prostate cancer cells to grow and the cancer to progress.
Mevrometostat, the study medicine, is thought to work by blocking the abnormal EZH2 activity in cells, which may help prevent or delay hormone therapy resistance and cancer growth and progression.
Participating in these studies
MEVPRO is enrolling adults who have metastatic prostate cancer. Each clinical trial in the MEVPRO program will have its own unique requirements for who may participate. If you have developed resistance to available treatments and your cancer has spread to other parts of the body, the MEVPRO clinical trials may be an option for you. The requirements may include your stage of prostate cancer and any previous treatments you may have received.
You can talk with the study doctor to find out which trial may be right for you.
Joining a clinical trial is an important and personal decision. Thank you for your consideration.
Condition
Metastatic prostate cancer
Age
18+ years
Sex
Male
This information is a summary of the eligibility criteria across the studies in this program. Each study will have its own unique requirements for who may participate (eligibility criteria). To learn more about the requirements for a study that is actively recruiting, visit the study’s webpage below. Only the research study staff can determine if you qualify to enroll in the study.
Pfizer MEVPRO Prostate Cancer clinical trials
Frequently asked questions
All study participants will receive standard-of-care treatment. Participants will either receive standard-of-care treatment alone, or standard-of-care treatment along with mevrometostat, the study medicine. Standard-of-care treatments are established treatments that are widely accepted by medical professionals and may vary depending on where a patient lives. The study doctor will explain this to you in more detail during the informed consent process.
The study medicine and any study-related procedures will generally be covered at no cost. You may be reimbursed for any reasonable expenses that you may have as a result of taking part in this clinical trial (such as parking, meals, or other travel-related expenses).
There are no guaranteed benefits to joining a clinical trial. You will have regular visits to the study site and your health and cancer will be closely monitored for the duration of the clinical trial.
Participating in clinical trials helps researchers learn more about the disease and advance potential treatment options. By joining one of the MEVPRO clinical trials, you may help men with metastatic prostate cancer in the future.
With taking any medicine, participants in clinical trials may experience side effects from the study treatment. The potential side effects may include vomiting, diarrhea, weight loss, decreased appetite, altered sense of taste, hair loss, nausea (feeling sick), fatigue (feeling tired), and asthenia (low energy). The study doctor will discuss all the possible risks and benefits of participating with you before you choose to enroll.
The length of your participation will depend on how your cancer responds, how well you tolerate the study medicine and your personal decision to remain in the clinical trial. If you choose to enroll, you will need to make visits to the study site for study treatment and follow up visits. The activities that take place during the study visits will also vary, but may include blood tests, an electrocardiogram, and medical imaging. Your study doctor will provide you with more information about the clinical trial, including study visit activities, during the informed consent process. If one of the MEVPRO clinical trials is a good fit for you and you decide to take part, it’s important to remember that joining is your choice, and you are free to stop being in a clinical trial at any time for any reason.
Diverse participation matters
Diverse participation matters
People of certain ethnicities are more likely to be diagnosed with prostate cancer. Black men are 70% more likely than White men to be diagnosed. Prostate cancer is also the most commonly diagnosed cancer among Hispanic men in the U.S., comprising more than 1 in 5 of all new cancer diagnoses.
However, these two groups are underrepresented in US prostate cancer trials:
- Around 10% of participants were Black men
- Less than 5% of participants were Hispanic men
Many factors, including genetics, race, and ethnicity, can impact how people respond to a medicine. That is why it is so important that clinical trials include people of all backgrounds. The greater the diversity among clinical trial participants the more we can learn about potential medicines, including how they work for different people.
When you or a loved one choose to participate in a clinical trial, you are helping to build a greater understanding of your type of prostate cancer and bringing hope to all people living with cancer.
